Evofem Biosciences (Evofem Biosciences) FCF Margin % : -3.51% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Evofem Biosciences's Free Cash Flow for the three months ended in Dec. 2023 was $-0.17 Mil. Evofem Biosciences's Revenue for the three months ended in Dec. 2023 was $4.84 Mil. Therefore, Evofem Biosciences's FCF Margin % for the quarter that ended in Dec. 2023 was -3.51%.

As of today, Evofem Biosciences's current FCF Yield % is -1,507.90%.

The historical rank and industry rank for Evofem Biosciences's FCF Margin % or its related term are showing as below:

EVFM' s FCF Margin % Range Over the Past 10 Years
Min: -24009.64 Med: -1117.47 Max: -49.25
Current: -49.25

During the past 12 years, the highest FCF Margin % of Evofem Biosciences was -49.25%. The lowest was -24009.64%. And the median was -1117.47%.

EVFM's FCF Margin % is ranked better than
62.12% of 1040 companies
in the Biotechnology industry
Industry Median: -141.08 vs EVFM: -49.25

Evofem Biosciences FCF Margin % Historical Data

The historical data trend for Evofem Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences FCF Margin % Chart

Evofem Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-24,009.64

-1,814.73

-420.21

-49.25

Evofem Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-3,627.62	-85.09	-60.82	-46.24	-3.51

Competitive Comparison of Evofem Biosciences's FCF Margin %

For the Biotechnology subindustry, Evofem Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's FCF Margin % falls into.

Evofem Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Evofem Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.972	/	18.218
	=	-49.25 %

Evofem Biosciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.17	/	4.839
	=	-3.51 %

Evofem Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evofem Biosciences (Evofem Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122

Website

https://www.evofem.com

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

Executives

Yan Zhang	officer: Chief Financial Officer	6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar	director, 10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip	director	12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca	officer: Chief Commercial Officer	12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier	director, officer: Chief Executive Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: General Counsel and Secretary	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File	officer: Chief Financial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans	officer: Chief Commercial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd.	10 percent owner	1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd	10 percent owner	65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp	10 percent owner	767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell	officer: Chief Medical Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130